Clinical Trial Update: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) [Phase 1]

View source ↗

Summary

Phase 1 safety, pharmacokinetic, and pharmacodynamic study of NKTT120 in adults with stable sickle cell disease. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• NKTT120

Snippet

Sponsor: NKT Therapeutics | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED